Advances in the Pathogenesis and Possible Treatments for Multiple Hereditary Exostoses from the 2016 International MHE Conference

Total Page:16

File Type:pdf, Size:1020Kb

Advances in the Pathogenesis and Possible Treatments for Multiple Hereditary Exostoses from the 2016 International MHE Conference Connective Tissue Research ISSN: 0300-8207 (Print) 1607-8438 (Online) Journal homepage: https://www.tandfonline.com/loi/icts20 Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference Anne Q. Phan, Maurizio Pacifici & Jeffrey D. Esko To cite this article: Anne Q. Phan, Maurizio Pacifici & Jeffrey D. Esko (2018) Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference, Connective Tissue Research, 59:1, 85-98, DOI: 10.1080/03008207.2017.1394295 To link to this article: https://doi.org/10.1080/03008207.2017.1394295 Published online: 03 Nov 2017. Submit your article to this journal Article views: 323 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=icts20 CONNECTIVE TISSUE RESEARCH 2018, VOL. 59, NO. 1, 85–98 https://doi.org/10.1080/03008207.2017.1394295 PROCEEDINGS Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference Anne Q. Phana, Maurizio Pacificib, and Jeffrey D. Eskoa aDepartment of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA, USA; bTranslational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA ABSTRACT KEYWORDS Multiple hereditary exostoses (MHE) is an autosomal dominant disorder that affects about 1 in 50,000 Multiple hereditary children worldwide. MHE, also known as hereditary multiple exostoses (HME) or multiple osteochon- exostoses; multiple dromas (MO), is characterized by cartilage-capped outgrowths called osteochondromas that develop osteochondromas; EXT1; adjacent to the growth plates of skeletal elements in young patients. These benign tumors can affect EXT2; heparan sulfate; growth plate; skeletal growth plate function, leading to skeletal growth retardation, or deformations, and can encroach on development nerves, tendons, muscles, and other surrounding tissues and cause motion impairment, chronic pain, and early onset osteoarthritis. In about 2–5% of patients, the osteochondromas can become malig- nant and life threatening. Current treatments consist of surgical removal of the most symptomatic tumors and correction of the major skeletal defects, but physical difficulties and chronic pain usually continue and patients may undergo multiple surgeries throughout life. Thus, there is an urgent need to find new treatments to prevent or reverse osteochondroma formation. The 2016 International MHE Research Conference was convened to provide a forum for the presentation of the most up-to-date and advanced clinical and basic science data and insights in MHE and related fields; to stimulate the forging of new perspectives, collaborations, and venues of research; and to publicize key scientific findings within the biomedical research community and share insights and relevant information with MHE patients and their families. This report provides a description, review, and assessment of all the exciting and promising studies presented at the Conference and delineates a general roadmap for future MHE research targets and goals. Introduction threatening, because of their common resistance to chemo- or radiation therapy (5,6). No new osteochondro- Multiple hereditary exostoses (MHE) is a rare, pediatric, mas form after the end of puberty when all the growth and autosomal dominant musculoskeletal disorder that plates close and the skeleton reaches maturity. affects about 1 in 50,000 children worldwide (1,2). Current treatments for MHE mainly consist of surgical MHE, also known as Hereditary Multiple Exostoses removal of the most symptomatic tumors and correction (HME) or Multiple Osteochondromas (MO), is amongst of major skeletal defects such as deformations, limb the most common disorders within the NIH Office of length discrepancies, and joint ankylosis, and patients Rare Diseases classification and one of the most frequent often undergo more than 40–50 surgeries by age 18 (7). causes of bone tumors. As its name implies, MHE is However, because the osteochondromas are so numerous characterized by osteochondromas, benign cartilage- and often difficult to reach and resect, many are left in capped outgrowths with a bony stem developing adjacent place; consequently, a considerable number of patients to the growth plates of long bones, vertebrae, ribs, and struggle with pain and physical difficulties through life pelvis in juvenile patients (3,4). The tumors can affect the (8,9). As recent studies indicate, patients can suffer from normal functioning of growth plates, leading to growth additional non-skeletal health problems that include retardation and skeletal deformations. They can also social and learning difficulties, sleep disorders, and neu- impinge on nerves, tendons, blood vessels, muscles, and ropathies (10–12). MHE may also involve alterations in other surrounding tissues, causing motion impairment, postprandial lipid clearance and pancreatic beta-cell chronic pain, and even early onset osteoarthritis. In reserve due to smaller pancreas volume (13,14), making about 2–5% of patients, the osteochondromas transform MHE a syndrome rather than a pure skeletal condition. into malignant chondrosarcoma that can be life CONTACT Jeffrey D. Esko [email protected] Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093- 0687, USA. © 2017 Taylor & Francis 86 A. Q. PHAN ET AL. MHE is linked to heterozygous loss-of-function muta- perichondrium (35–37). Other studies showed that chon- tions in EXT1 (8q24.1) or EXT2 (11p11-12) (15–17)that drocytes in zebrafish mutants lacking dackel (correspond- encode Golgi-associated glycosyltransferases responsible ing to mammalian Ext2) grew aberrantly and lost polarity, for the biosynthesis of heparan sulfate (HS) (18). HS is a invading surrounding tissues, thus mimicking traits of complex glycosaminoglycan polymerized from alternat- MHE chondrocytes (38). Human MHE growth plate ing N-acetylglucosamine and glucuronic acid residues, chondrocytes display disorganized primary cilia and loss and both EXT1 (the enzyme) and EXT2 (the chaperone- of cellular polarity, suggesting that the cells were unable to like and non-enzymatically active partner of EXT1) are perceive cilia-mediated signals and maintain cell align- needed for its synthesis (19,20). The HS chains are poly- ment and location, thus contributing to osteochondromas merized and covalently linked to small subset of HS-rich (39). Huegel et al. showed that Ext1 and HS regulate proteoglycans (HSPGs) and undergo extensive, concur- perichondrial phenotype and border function in develop- rent chain modifications including sulfation at various ing long bones and that the loss of Ext1 in perichondrial positions and glucuronic acid epimerization, resulting in progenitor cells led to osteochondroma formation (40). chains with a high degree of structural complexity and Boundary defects may be reinforced by changes in biological specificity (21,22). The HSPG family includes microRNAs demonstrated in MHE chondrocytes (41). cell surface proteoglycans (4 syndecans, 6 glypicans, Studies also indicated that the HS deficiency in MHE CD44V3, betaglycan, and CD47), pericellular/extracellu- cartilage and perichondrium could be exacerbated by lar matrix proteoglycans (perlecan, agrin, and Type XVIII abnormally high expression of heparanase (42,43). In collagen), and serglycin (21,23,24). The HSPGs are summary, there has been significant progress in uncover- expressed in a tissue-specific manner and have a number ing aspects of the genetics and cellular pathogenesis of of important developmental and physiologic functions MHE using both animal models and human MHE speci- (24). One of their main roles is to interact with growth mens. However, much remains to be understood factors, morphogens, and receptors, all characterized by mechanistically, and relatively little has been achieved so possessing a specific HS-binding domain (25,26). The far toward the development of treatments to prevent HSPGs regulate protein availability, distribution, turn- osteochondroma formation and/or growth (44). over, and signaling, thus affecting cell adhesion and As pointed out above, MHE is not simply a skeletal migration, cell–cell interactions and communication, disease, but encompasses non-skeletal pathologies (9). cell differentiation and morphogenesis, and lipoprotein Unlike skeletal abnormalities, these additional patholo- metabolism and proteases involved in hemostasis and gies occur with varying frequency and have been dis- development (21,23,24). The EXT deficiency in MHE counted or unappreciated in the past. However, recent results in partial truncation of the HS chains, which human and mouse studies have provided evidence that leads to lower levels of HS in multiple tissues and plasma HS deficiency can in fact cause physiological defects in (27–29), potentially explaining the impact of the muta- kidney organization and podocyte structure (13), neuro- tions on multiple organ systems. nal cell signaling and mouse behavior (45,46), lipid The haploinsufficiency in EXT1 or EXT2 in MHE metabolism (47,48), intestinal epithelial barrier function patients can in itself cause certain pathologies
Recommended publications
  • Multiple Hereditary Exostoses Abstract Book, 2005
    CONFERENCE ON Multiple Hereditary Exostoses InsightsInsights IntoInto PathogenesisPathogenesis November 3-5, 2005 Shriners Hospital of Houston 6977 Main Street Houston, Texas and the Houston Marriott Medical Center 6580 Fannin Street Houston, Texas Organizers: Dan Wells, Ph.D., Jacqueline Hecht, Ph.D., Sarah Ziegler Sponsored By: The Shriners Hospital The National Institutes of Health American Association of Enchondroma Diseases March of Dimes Birth Defects Foundation The Orthopaedic Research Society The MHE Coalition Gene Dx, DNA Diagnostic Services The Mizutani Foundation for Glycoscience HME: Insights into Pathogenesis. Schedule of Events Thursday November 3, 2005 8:30-9:00 Arrive at Shriners (Coffee and Pastries) 9:00-9:10 Dan Wells, Ph.D. Welcome to conference 9:10-9:30 Jacqueline Hecht, Ph.D. Introduction to genetics and natural history MHE ORTHOPAEDICS AND CLINICAL GENETICS (Christine Alvarez) 9:30-10:10 Christine Alvarez, M.D. Introduction of orthopaedics and defining severity of Hereditary Multiple Exostosis 10:10-10:40 Luca Sangiorgi, M.D., Ph.D. Mutational analysis and clinical expression of disease in patients with HME. 10:40-11:00 BREAK 11:00-11:30 Wim Wuyts, Ph.D. Mutation detection strategies for molecular screening in patients with HME. 11:30-12:00 George Thompson, M.D. Clinical treatments and surgical procedures. 12:00-1:15 LUNCH BONE DEVELOPMENT (Dan Wells) 1:15-1:45 John R. Hassell, Ph.D. FGF binding to percelan isolated from the growth plate. 1:45-2:15 David Ornitz, M.D., Ph.D. FGF that regulate growth plate development. 2:15-2:45 Maurizio Pacifici, M.D., Ph.D.
    [Show full text]
  • Bone and Soft Tissue Tumors Have Been Treated Separately
    EPIDEMIOLOGY z Sarcomas are rare tumors compared to other BONE AND SOFT malignancies: 8,700 new sarcomas in 2001, with TISSUE TUMORS 4,400 deaths. z The incidence of sarcomas is around 3-4/100,000. z Slight male predominance (with some subtypes more common in women). z Majority of soft tissue tumors affect older adults, but important sub-groups occur predominantly or exclusively in children. z Incidence of benign soft tissue tumors not known, but Fabrizio Remotti MD probably outnumber malignant tumors 100:1. BONE AND SOFT TISSUE SOFT TISSUE TUMORS TUMORS z Traditionally bone and soft tissue tumors have been treated separately. z This separation will be maintained in the following presentation. z Soft tissue sarcomas will be treated first and the sarcomas of bone will follow. Nowhere in the picture….. DEFINITION Histological z Soft tissue pathology deals with tumors of the classification connective tissues. of soft tissue z The concept of soft tissue is understood broadly to tumors include non-osseous tumors of extremities, trunk wall, retroperitoneum and mediastinum, and head & neck. z Excluded (with a few exceptions) are organ specific tumors. 1 Histological ETIOLOGY classification of soft tissue tumors tumors z Oncogenic viruses introduce new genomic material in the cell, which encode for oncogenic proteins that disrupt the regulation of cellular proliferation. z Two DNA viruses have been linked to soft tissue sarcomas: – Human herpes virus 8 (HHV8) linked to Kaposi’s sarcoma – Epstein-Barr virus (EBV) linked to subtypes of leiomyosarcoma z In both instances the connection between viral infection and sarcoma is more common in immunosuppressed hosts.
    [Show full text]
  • Exostoses, Enchondromatosis and Metachondromatosis; Diagnosis and Management
    Acta Orthop. Belg., 2016, 82, 102-105 ORIGINAL STUDY Exostoses, enchondromatosis and metachondromatosis; diagnosis and management John MCFARLANE, Tim KNIGHT, Anubha SINHA, Trevor COLE, Nigel KIELY, Rob FREEMAN From the Department of Orthopaedics, Robert Jones Agnes Hunt Hospital, Oswestry, UK We describe a 5 years old girl who presented to the region of long bones and are composed of a carti- multidisciplinary skeletal dysplasia clinic following lage lump outside the bone which may be peduncu- excision of two bony lumps from her fingers. Based on lated or sessile, the knee is the most common clinical examination, radiolographs and histological site (1,10). An isolated exostosis is a common inci- results an initial diagnosis of hereditary multiple dental finding rarely requiring treatment. Disorders exostosis (HME) was made. Four years later she developed further lumps which had the radiological associated with exostoses include HME, Langer- appearance of enchondromas. The appearance of Giedion syndrome, Gardner syndrome and meta- both exostoses and enchondromas suggested a possi- chondromatosis. ble diagnosis of metachondromatosis. Genetic testing Enchondroma are the second most common be- revealed a splice site mutation at the end of exon 11 on nign bone tumour characterised by the formation of the PTPN11 gene, confirming the diagnosis of meta- hyaline cartilage in the medulla of a bone. It occurs chondromatosis. While both single or multiple exosto- most frequently in the hand (60%) and then the feet. ses and enchondromas occur relatively commonly on The typical radiological features are of a well- their own, the appearance of multiple exostoses and defined lucent defect with endosteal scalloping and enchondromas together is rare and should raise the differential diagnosis of metachondromatosis.
    [Show full text]
  • Post-Traumatic Osteolysis of the Clavicle: a Case Report C
    Arch Emerg Med: first published as 10.1136/emj.3.2.129 on 1 June 1986. Downloaded from Archives of Emergency Medicine, 1986, 3, 129-132 Post-traumatic osteolysis of the clavicle: a case report C. J. GRIFFITHS AND E. GLUCKSMAN Department ofAccident and Emergency Medicine, King's College Hospital, Denmark Hill, London, England SUMMARY A case of post-traumatic osteolysis of the clavicle occurring in a 25-year-old male is described. The condition should be suspected in anyone giving a history of persistent shoulder pain following trauma or intensive sporting activities. Characteristic resorp- tion of the distal tip of the clavicle is found on X-ray. The condition usually responds by copyright. within 2 years to conservative treatment. Previous reports ofthe condition are reviewed, and the possible pathogenesis and differential diagnosis discussed. INTRODUCTION Post-traumatic osteolysis of the clavicle is an uncommon condition characterized by http://emj.bmj.com/ persistent shoulder pain associated with decalcification of the distal tip of the clavicle following trauma to the acromio-clavicular joint (Madsen, 1963; Smart, 1972; Quinn & Glass, 1983). Patients usually give a history of previous trauma to the shoulder, but the condition may follow active sports such as weight training (Cahill, 1982) or the use of pneumatic tools (Ehricht, 1959). The condition usually resolves within 2 years in the absence of further trauma. This article describes a case of post-traumatic osteolysis of on September 28, 2021 by guest. Protected the clavicle, and discusses the diagnosis and possible pathogenesis of the condition. CASE REPORT A 25-year-old medical student (C.G.) was involved in a bicycle accident and received a direct blow to his right shoulder.
    [Show full text]
  • SKELETAL DYSPLASIA Dr Vasu Pai
    SKELETAL DYSPLASIA Dr Vasu Pai Skeletal dysplasia are the result of a defective growth and development of the skeleton. Dysplastic conditions are suspected on the basis of abnormal stature, disproportion, dysmorphism, or deformity. Diagnosis requires Simple measurement of height and calculation of proportionality [<60 inches: consideration of dysplasia is appropriate] Dysmorphic features of the face, hands, feet or deformity A complete physical examination Radiographs: Extremities and spine, skull, Pelvis, Hand Genetics: the risk of the recurrence of the condition in the family; Family evaluation. Dwarf: Proportional: constitutional or endocrine or malnutrition Disproportion [Trunk: Extremity] a. Height < 42” Diastrophic Dwarfism < 48” Achondroplasia 52” Hypochondroplasia b. Trunk-extremity ratio May have a normal trunk and short limbs (achondroplasia), Short trunk and limbs of normal length (e.g., spondylo-epiphyseal dysplasia tarda) Long trunk and long limbs (e.g., Marfan’s syndrome). c. Limb-segment ratio Normal: Radius-Humerus ratio 75% Tibia-Femur 82% Rhizomelia [short proximal segments as in Achondroplastics] Mesomelia: Dynschondrosteosis] Acromelia [short hands and feet] RUBIN CLASSIFICATION 1. Hypoplastic epiphysis ACHONDROPLASTIC Autosomal Dominant: 80%; 0.5-1.5/10000 births Most common disproportionate dwarfism. Prenatal diagnosis: 18 weeks by measuring femoral and humeral lengths. Abnormal endochondral bone formation: zone of hypertrophy. Gene defect FGFR fibroblast growth factor receptor 3 . chromosome 4 Rhizomelic pattern, with the humerus and femur affected more than the distal extremities; Facies: Frontal bossing; Macrocephaly; Saddle nose Maxillary hypoplasia, Mandibular prognathism Spine: Lumbar lordosis and Thoracolumbar kyphosis Progressive genu varum and coxa valga Wedge shaped gaps between 3rd and 4th fingers (trident hands) Trident hand 50%, joint laxity Pathology Lack of columnation Bony plate from lack of growth Disorganized metaphysis Orthopaedics 1.
    [Show full text]
  • Management of the 'Young' Patient with Hip Disease
    ARTHROPLASTY OF THE LOWER EXTREMITIES Management of the ‘Young’ Patient with Hip Disease SCOTT A. RITTERMAN, MD; LEE E. RUBIN, MD ABSTRACT abnormalities lead to impingement within the joint, altered Although hip arthritis typically affects older patients, biomechanics and ultimately cartilage loss.2 Secondary there is a rapidly growing population of “young” patients osteoarthritis can be due to an identifiable cause such as experiencing debilitating symptoms from hip disease. trauma to the femoral head, post-infection arthritis, slipped Most commonly, osteoarthritis and avascular necrosis af- capital femoral epiphysis, or hip dysplasia. fect this population, but a variety of other primary struc- As we age, the water content of cartilage increases with tural and metabolic causes can also occur. The expecta- a concomitant decrease in protein content, both leading to tions of these younger patients are often distinct from degeneration. The progressive loss of the cartilage matrix geriatric patients, and the challenges in optimizing their leads to recurrent bouts of inflammation as bone contacts care are unique in this demanding population. Selection bone, and reactive bone called osteophyte forms around the of the implant, bearing surface, and surgical technique joint. In the subchondral bone, hardening and cyst formation can all impact the success and longevity of total hip re- occurs. Repeated bouts of inflammation also extend into the placement. A consideration for respecting the native peri-articular soft tissues leading to deformity and contrac- bone stock is an important consideration that can poten- tures of the capsule, supporting ligaments, and tendons. Put tially reduce some of the future challenges of revision ar- together, these changes lead to pain, stiffness, and gait dis- throplasty in this young population.
    [Show full text]
  • Imaging in Osteogenesis Imperfecta
    Paediatr Croat. 2017;61:122-8 PREGLED / REVIEW www.paedcro.com http://dx.doi.org/10.13112/PC.2017.17 Imaging in osteogenesis imperfecta Igor Borić, Renata Prpić Vučković* Osteogenesis imperfecta (OI) is a congenital genetic disorder with skeletal or extra-skeletal manifestations. Phenotypic features and mode of inheritance, clinical features, and radiographic fi ndings make the basis for the currently accepted classifi cation system of OI. The antenatal and postnatal diagnosis of the disease using diff erent radiographic methods (plain radiography, ultrasonography, computed tomography and magnetic resonance imaging) is described and characteristic appearances of bone and other defor- mities are analyzed. Distinctive bone manifestations of OI are illustrated using typical examples. Finally, we give a comment on diff erential diagnosis. Key words: osteogenesis imperfecta, radiography, imaging Osteogenesis imperfecta (OI) is a congenital, genetic disor- od: radiography, ultrasonography (US), computed tomogra- der of collagen type I synthesis that involves connective tis- phy (CT) and magnetic resonance imaging (MRI) (3, 7, 8). sues and bones, and is characterized by increased bone The preferred radiographic examination for initial investiga- fragility and decreased bone density. There is extreme varia- tion of OI is plain radiography because most of the imaging tion in clinical symptoms based on genetics and subtypes characteristics of this disease are apparent on plain radio- including blue sclera, dental fragility, and hearing loss. De- graphs. pending on the disease severity, bone fragility may lead to Prenatal ultrasonography plays a role in the diagnosis of OI; perinatal death or can cause severe deformities that persist typical fi ndings include fractures, decreased calvarial ossifi ca- into adulthood (1, 2).
    [Show full text]
  • Pathological Fracture of the Tibia As a First Sign Of
    ANTICANCER RESEARCH 41 : 3083-3089 (2021) doi:10.21873/anticanres.15092 Pathological Fracture of the Tibia as a First Sign of Hyperparathyroidism – A Case Report and Systematic Review of the Current Literature ALEXANDER KEILER 1, DIETMAR DAMMERER 1, MICHAEL LIEBENSTEINER 1, KATJA SCHMITZ 2, PETER KAISER 1 and ALEXANDER WURM 1 1Department of Orthopaedics and Traumatology, Medical University of Innsbruck, Innsbruck, Austria; 2Institute for Pathology, INNPATH GmbH, Innsbruck, Austria Abstract. Background/Aim: Pathological fractures are rare, of the distal clavicles, a “salt and pepper” appearance of the suspicious and in some cases mentioned as the first sign of a skull, bone cysts, and brown tumors of the bones (3). malignant tumor. We present an uncommon case with a Primary hyperparathyroidism (PHPT), also known as “brown pathological fracture of the tibia diaphysis as the first sign of tumor”, also involves unifocal or multifocal bone lesions, which severe hyperparathyroidism. Case Report: We report the case represent a terminal stage of hyperparathyroidism-dependent of a female patient who was referred to the emergency bone pathology (4). This focal lesion is not a real neoplasm. In department with a history of progressively worsening pain in localized regions where bone loss is particularly rapid, the lower left leg and an inability to fully bear weight. No hemorrhage, reparative granulation tissue, and active, vascular, history of trauma or any other injury was reported. An x-ray proliferating fibrous tissue may replace the healthy marrow revealed an extensive osteolytic lesion in the tibial shaft with contents, resulting in a brown tumor. cortical bone destruction. Conclusion: Our case, together with Histologically, the tumor shows bland spindle cell very few cases described in the current literature, emphasizes proliferation with multinucleated osteoclastic giant cells and that in the presence of hypercalcemia and lytic lesions primary signs of bone resorption.
    [Show full text]
  • Multiple Hereditary Exostoses
    Multiple Hereditary Exostoses Dror Paley MD, FRCSC Medical Director, Paley Orthopedic and spine Institute, St. Mary’s Medical Center, West palm Beach, FL David Feldman, MD Director, Spinal deformity center, Paley Orthopedic and spine Institute, St. Mary’s Medical Center, West palm Beach, FL Multiple hereditary exostoses (MHE), also known as multiple osteochondromas (MO), is an autosomal dominant skeletal disorder. Approximately 10–20% of individuals are a result of a spontaneous mutation while the rest are familial. The prevalence of MHE/MO is 1/50 000. There are two known genes found to cause MHE/MO, EXT1 located on chromosome 8q23-q24 and EXT2 located on chromosome 11p11-p12. In 10–15% of the patients, no mutation can be located by current methods of genetic testing.1–7 These mutations are scattered across both genes. EXT1/EXT2 is essential for the biosynthesis of heparan sulfate (HS). HS production in patients’ cells is reduced by 50% or more.8–19 MHE/MO is associated with characteristic progressive skeletal deformities of the extremities and shortening of one or both the sides, leading to limb length discrepancy (LLD) and short stature.20–28 Two bone segments, such as the lower leg or forearm, are at greater risk of problems due to either osteochondromas (OCs) from one or both bones impinging on or deforming the other bone or a primary issue of altered growth causing one bone to grow at a faster or slower rate. OCs can also affect joint motion due to impingement of an OC with the opposite side of the joint or subluxation/dislocation related to deformity, impingement, and incongruity.20,24,26,29,30 OCs can also cause nerve or vessel entrapment and/or compression, including the spinal cord and nerve roots.
    [Show full text]
  • Treatment of Phalanx Enchondroma by Autograft Harvested from the Bone with Osteopoikilosis: a Case Report
    CASE REPORT Acta Medica Alanya 2017 Cilt : 1 Sayı : 2 OLGU SUNUMU Treatment Of Phalanx Enchondroma By Autograft Harvested From The Bone With Osteopoikilosis: A Case Report Falanks Enkondromunun Osteopoıkılozlu Kemikten Alınan Otogreft ile Tedavisi: Olgu Sunumu Gökhan Peker1, Sunkar Kaya Bayrak2, Alkan Bayrak3*, Dila Mete Peker4 1. Trabzon Kanuni Eğitim ve Araştırma Hastanesi Ortopedi ve Travmatoloji Kliniği, Trabzon, Türkiye. 2. Saglik Bakanliği Turhal Devlet Hastanesi, Anestezi ve Reanimasyon Servisi, Turhal, Tokat, Türkiye 3. Saglik Bakanliği Turhal Devlet Hastanesi, Ortopedi ve Travmatoloji Servisi, Turhal, Tokat, Türkiye 4. Trabzon Kanuni Eğitim ve Araştırma Hastanesi İç Hastaliklari Kliniği, Trabzon, Türkiye. ABSTRACT ÖZET Osteopoikilosis is a rare bone dysplasia characterized by abnormally enchondral Osteopoikiloz, çocukluk çağında gelişmeye başlayan ve ileri yaşlarda devam eden, bone maturation, which generally stars to be formed in the childhood and continues enkondral kemik matürasyonunda anormallikle karakterize, nadir görülen bir kemik in the adulthood. It is generally asemptomatic and it is determined incidentally. As it is displazisidir. Sıklıkla asemptomatik olmakla beraber genellikle rastlantısal olarak generally inherited otosomal dominantly, sporadic cases can also be seen. Enchon- saptanır. Otozomal dominant geçişli olan patoloji, sporadik olarak da görülebilmekte- droma is a benign lesion formed from hyaline cartilage mostly in small bones like foot dir. Enkondrom ise klasik olarak hiyalin kıkırdak kökenli benign, ayak ve el kemikleri and hand with longitudinal and elliptic shape. In this study, we would like to discuss gibi küçük kemiklerde yerleşmiş olan uzunlamasına ve oval kemik lezyonlarıdır. Bu the patient with phalangeal enchondroma and osteopoikilosis. çalışmamızda, osteopoikiloz tanılı ve falanksında enkondrom oluşan olgumuzu sun- mayı ve tedavisini tartışmayı amaçladık.
    [Show full text]
  • (Ollier Disease, Maffucci Syndrome) Is Not Caused by the PTHR1 Mutation
    Enchondromatosis (Ollier Disease, Maffucci Syndrome) Is Not Caused by the PTHR1 Mutation p.R150C Bovée, J.V.M.G.; Rozeman, L.B.; Sangiorgi, L.; Briaire-de Bruijn, I.H.; Mainil-Varlet, P.; Bertoni, F.; ... ; Hogendoorn, P.C.W. Citation Bovée, J. V. M. G., Rozeman, L. B., Sangiorgi, L., Briaire-de Bruijn, I. H., Mainil-Varlet, P., Bertoni, F., … Hogendoorn, P. C. W. (2004). Enchondromatosis (Ollier Disease, Maffucci Syndrome) Is Not Caused by the PTHR1 Mutation p.R150C. Human Mutation, 24, 466-473. Retrieved from https://hdl.handle.net/1887/8144 Version: Not Applicable (or Unknown) License: Downloaded from: https://hdl.handle.net/1887/8144 Note: To cite this publication please use the final published version (if applicable). HUMAN MUTATION 24:466^473 (2004) RAPID COMMUNICATION Enchondromatosis (Ollier Disease, Maffucci Syndrome) Is Not Caused by the PTHR1 Mutation p.R150C Leida B. Rozeman,1 Luca Sangiorgi,2 Inge H. Briaire-de Bruijn,1 Pierre Mainil-Varlet,3 F. Bertoni,4 Anne Marie Cleton-Jansen,1 Pancras C.W. Hogendoorn,1 and Judith V.M.G. Bove´e1* 1Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 2Laboratory of Oncology Research, Rizzoli Orthopedic Institute, Bologna, Italy; 3Institute of Pathology, University of Bern, Bern, Switzerland; 4Department of Pathology, Rizzoli Orthopedic Institute, Bologna, Italy Communicated by Arnold Munnich Enchondromatosis (Ollier disease, Maffucci syndrome) is a rare developmental disorder characterized by multiple enchondromas. Not much is known about its molecular genetic background. Recently, an activating mutation in the parathyroid hormone receptor type 1 (PTHR1) gene, c.448C>T (p.R150C), was reported in two of six patients with enchondromatosis.
    [Show full text]
  • Benign Bone Tumors of the Foot and Ankle
    CHAPTER 20 BENIGN BONE TUMORS OF THE FOOT AND ANKLE, Robert R. Miller, D.P.M. Stephen V. Corey, D.P.M. Benign bone tumors of the foot and ankle typically Table 1 displays the percentage of each lesion present both a diagnostic and therapeutic challenge found in the leg and foot. The lesions represent a to podiatric surgeons. These lesions have a percentage of local lesions compared to the total relatively low incidence of occuffence in the foot number of lesions reported for the studies. It does and ankle when compared to other regions of the seem apparent that the overall incidence of foot body, and the behavior of these lesions may mimic and ankle involvement is relatively low, but some malignant tumors. Not only is it impofiant to tumors do occur with a somewhat frequent rate. recognize a specific lesion to insure proper treat- Primarily, enchondroma, osteochondroma, osteoid ment, but the ability to differentiate a benign from osteoma, simple (unicameral) bone cysts, and malignant process is of utmost importance. aneurysmal bone cysts are somewhat common in It is difficult to determine the true incidence of the foot and ankle. benign bone tumors of the foot and ankle. Most large studies do not distinguish individual tarsal RADIOGRAPHIC CHARACTERISTICS OF bones, nor is there a distinction made befween BENIGN BONE TUMORS proximal and distal aspects of the tibia and fibula. Dahlin's Bone Tumors has reported findings of the Several radiographic parameters have been Mayo Clinic up until 7993.' total 2334 Of a of described to differentiate between benign and benign bone tumors affecting the whole body, malignant bone tumors.
    [Show full text]